A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
130actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-16 | actual | When the study began enrolling |
| Primary completion | 2026-03-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-20 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Facial Contouring
Interventions
- Drug: OnabotulinumtoxinA
- Device: JUVÉDERM — also filed as VOLUX XC, VOLUMA XC, VOLLURE XC, VOLBELLA XC, SKINVIVE, ULTRA PLUS XC, ULTRA XC
- Device: CoolSculpting Elite System
- Other: SkinMedica Products
- Drug: KYBELLA
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Satisfaction with Facial Appearance Scale at the Final Visit
measured Up to approximately 284 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed